NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

CompletedN/A

Sponsor: AstraZeneca

Conditions: Ovary Cancer

Interventions: Olaparib

Countries: France, Italy, United Kingdom

This is a retrospective observational medical records review study of BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting in France, Italy and the UK. Physicians who treated ovarian cancer patients with olaparib in 1L setting will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III - IV) epithelial ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer who have completed first line platinum-based chemotherapy, in PR/CR and treated with at least one dose of olaparib in first line maintenance setting
* Patients aged ≥18 years old
* Ability and/or willingness to provide a signed informed consent form (where required)

Exclusion Criteria:

* Withdrawal of informed consent (where consent required)
* Concurrent participation in any clinical study with an investigational product at the time of olaparib initiation

Locations (55)

Avignon, France
Besançon, France
Bordeaux, France
Bourg-en-Bresse, France
Calais, France
Chambray-lès-Tours, France
Epagny Metz-Tessy, France
Grenoble, France
Langon, France
Lyon, France
Nancy, France
Paris, France
Pierre-Bénite, France
Roubaix, France
Saint-Cloud, France
Saint-Grégoire, France
Suresnes, France
Tours, France
Villejuif, France
Acquaviva delle Fonti, Italy
Aviano, Italy
Bari, Italy
Bologna, Italy
Cagliari, Italy
Catania, Italy
Florence, Italy
Genova, Italy
Milan, Italy
Milan, Italy
Milan, Italy
+ 25 more on CT.gov